Original Article

Ad-HGF improves the cardiac remodeling of rat following myocardial infarction by upregulating autophagy and necroptosis and inhibiting apoptosis

Jiabao Liu¹, Peng Wu¹, Yunle Wang¹, Yingqiang Du¹, Nan A¹, Shuiyuan Liu¹, Yiming Zhang¹, Ningtian Zhou¹, Zhihui Xu¹, Zhijian Yang¹,²

Departments of ¹Cardiology, ²Geriatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Received July 21, 2016; Accepted October 30, 2016; Epub November 15, 2016; Published November 30, 2016

Abstract: Cell death in MI is the most critical determinant of subsequent left ventricular remodeling and heart failure. Besides apoptosis, autophagy and necroptosis have been recently found to be another two regulated cell death styles. HGF has been reported to have a protective role in MI, but its impact on the three death styles remains unclear. Thus, our study was performed to investigate the distribution of autophagy, apoptosis and necroptosis in cardiac tissues after MI and explore the role and mechanism of Ad-HGF on cardiac remodeling by regulating the three death styles. We firstly showed the distribution of autophagy, apoptosis and necroptosis differs in temporal and spatial context after MI using immunofluorescence. Notably, Ad-HGF treatment improves the cardiac remodeling of SD rats following MI by preserving the heart function, reducing the scar size and aggresomes. Further mechanism study reveals Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis in vivo and in vitro. Co-immunoprecipitation assays showed Ad-HGF treatment significantly decreased the binding of Bcl-2 to Beclin1 but enhanced Bcl-2 binding to Bax in H9c2 cells under hypoxia. Moreover, HGF-induced sequestration of Bax by Bcl-2 allows Bax to become inactive, thereby inhibiting apoptosis. In addition, Ad-HGF markedly increased the formation of Beclin1-Vps34-Atg14L complex, which accounted for promoting autophagy. Both the western blot and activity assay showed Ad-HGF significantly decreased the caspase 8 protein and activity levels, which obligated the cell to undergo necroptosis under hypoxia and block apoptosis. Thus, our findings offer new evidence and strategies for the treatment of MI and post-MI cardiac remodeling.

Keywords: Ad-HGF, myocardial infarction, cardiac remodeling, autophagy, apoptosis, necroptosis

Introduction

Myocardial infarction (MI) is one of the leading causes of morbidity and mortality worldwide and the incidence of which shows a rising trend in developing countries [1]. Advances in the treatment of MI, such as early reperfusion therapy, have notably reduced the mortality in patients with acute myocardial infarction. However, the parallel increase of the prevalence and mortality from left ventricular (LV) remodeling and heart failure after MI has emerged as a growing challenging health problem of concern [2]. Currently, therapeutic strategies to prevent adverse LV remodeling and heart failure after MI are still limited. Therefore, it’s highly needed to identify new therapeutic targets and treatment options to prevent post-MI adverse cardiac remodeling.

For many years, apoptosis was considered as the only form of regulated cell death and studies investigating myocyte cell death mainly focused on apoptosis [3, 4]. Recent years, autophagy and necroptosis have been found to be another two regulated cell death styles existing in various diseases including MI [5-7]. However, the distribution and roles of the three types of cell death in different periods and different regions of the heart after MI have not been fully elucidated. Study of autophagy, apoptosis and necroptosis in the process of myocardial infarction may provide us new insights to the treatment of MI and post-MI adverse cardiac remodeling.

Autophagy is an intracellular degradation process in which cytosolic proteins and organelles are confined into autophagosomes and
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis

degraded by lysosomes [6, 8]. Because of its large capacity, autophagy plays an important role in maintaining organelle functions and protein quality by degrading damaged organelles and protein aggregates. Suppression of autophagy below physiological levels through genetic deletion of Atg5 induces heart failure with enhanced protein aggregation, manifesting autophagy is actually required to maintain baseline heart function [9]. Autophagy is found to be upregulated in various pathological conditions, including myocardial ischemia and ischemia/reperfusion (I/R) [10-12]. It is generally compensatory for the upregulation of autophagy during myocardial stress, which on the one hand alleviating energy loss, on the other hand, scavenging damaged mitochondria and protein aggregates [10, 13].

Recently, a new death style, named necroptosis, was identified and proposed as a form of 'programmed necrosis', which was introduced in 2005 and demonstrated in cultured cells [14]. In contrast to apoptosis or autophagy, necroptosis is characterized by swollen organelles, disintegrated plasma membrane and lack of nuclear fragmentation [15]. Under the condition of various stimuli including TNF-α, ischemia and ischemia/reperfusion (I/R), etc., receptor interacting protein kinase 1 (RIP1) and receptor interacting protein kinase 3 (RIP3) auto- and transphosphorylate each other, and form necrosome, which then phosphorylates the pro-necrotic mixed lineage kinase domain-like (MLKL) protein. Necroptosis is initiated by phosphorylated MLKL through forming oligomerization which inserts itself into the membranes of organelles and plasma membrane [16, 17]. However, caspase-8 is able to disrupt the necrosome by cleaving RIP1 and RIP3, thereby effectively terminating necroptosis [17]. Thus, for necroptosis to ensue, the caspase-8 function must be compromised. But the interplay among autophagy, apoptosis and necroptosis has not been clearly elaborated.

Hepatocyte growth factor (HGF) is a multifunctional cytokine and its c-Met receptor is widely expressed in cardiovascular system including cardiomyocytes, endothelial cells and smooth muscle cells. Through phosphorylating its receptor and activating the downstream signaling pathway, HGF plays a series of biological effects including morphogenesis, stem cell maintenance and immunomodulation [18]. Studies have demonstrated the heart protective effect of HGF, which includes promoting angiogenesis, anti-fibrosis, anti-inflammation, myocardium protection and regeneration [19, 20]. Little evidence has shown that the protection of HGF is related with the myocytes adaptable autophagy, apoptosis and necroptosis after MI.

Thus, our study was performed to investigate the distribution of autophagy, apoptosis and necroptosis in cardiac tissues after MI and explore the role and mechanism of HGF on cardiac remodeling by regulating autophagy, apoptosis and necroptosis, which may offer new evidence and strategies for the treatment of MI and post-MI cardiac remodeling.

Materials and methods

Antibodies and reagents

The following antibodies were purchased from abcam: Anti-HGF antibody (ab83760), p62 (ab-91526), RIP1 (ab72139), anti-beta actin antibody (ab8226), anti-ATG14L antibody (ab139727), rabbit anti-mouse IgG H&L (HRP) antibody (ab6728); from sigma: RIP3 (R4277); from Cell Signaling (USA): Phospho-Met (Tyr1234/1235) antibody (#3077), LC3A/B (#4108), Beclin-1 (#3495), cleaved caspase 3 (#9664), caspase 3 (#9662), Bcl-2 (#2870), Bax (#2772), Vps34 (#4263), GAPDH (#5174); from Santa Cruz Biotechnology: Troponin I antibody (sc-133117), Met (sc-8057), Bcl-2 (sc-7382), Bcl-XL (sc-8392), MLKL (sc-165025). FITC or CY3 labeled secondary antibodies were purchased from Jackson ImmunoResearch (USA). ProteoStat® Aggresome Detection Kit was purchased from Enzo Life Sciences, Switzerland. TUNEL Cell Death Detection kit (Cat. No. 11684795910) and propidium iodide (PI) was purchased from Sigma, USA. Cell counting kit-8 (CCK-8) and Hoechst 33342 staining kit were purchased from KeyGEN BioTECH, China. Ad-mRFP-GFP-LC3 was purchased from HanBio Technology Co. Ltd, China. Ad-HGF adenovirus vectors were constructed as previously described [21, 22].

Animal model

SD rats (male, 180-220 g) were purchased from Nanjing Medical University Experimental Animal Center. All animal experiments were
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis

performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH publication No. 85-23, revised 1996) and approved by the Animal Care and Use Committee of Nanjing Medical University. Myocardial infarction was induced by permanent ligation of the left anterior descending (LAD) coronary artery. And the detailed operation procedure was as previously described [21]. A total of 50 microliter Ad-HGF (1.0×10⁹ PFU) or Ad-null (1.0×10⁹ PFU) was injected into the myocardium in the vicinity of the ischemic region (pale area) of the left ventricular wall immediately following ligation. Sham operations were carried out by the same method, but without tying the suture on the LAD. Rats were sacrificed using carbon dioxide (CO₂) at day 7 and 28, respectively.

Echocardiography

Cardiac structure and function were evaluated by echocardiography with Vevo 2100-a high resolution imaging system (Visual Sonics, Canada) with a MS-250, 16.0-21.0 MHZ imaging transducer at baseline, week 1 and week 4. All of the SD rats were anesthetized by ether before the process of echocardiography examination.

Assessment of LV scar size after chronic MI

Hearts of SD rats were fixed in 4% paraformaldehyde, cut into four transverse slices and subjected to Masson’s Trichrome staining for later measurement of the LV scar 28 days after MI. The average infarct size was obtained by calculation of the mean length of the circumference in the infarct region and the normal area from the consecutive myocardial slices.

Cell culture and treatment

H9c2 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Wisent Inc., Montreal, QC, Canada) supplemented with 10% (v/v) fetal bovine serum (FBS, Gibco, Grand Island, NY, USA), 100 U/ml of penicillin and 100 μg/ml of streptomycin. Cells were incubated at 37°C in a humidified air atmosphere supplemented with 5% CO₂. The culture mediums were changed every two days. AnaeroPack-Anaero (MGC, Japan) and anaerobic jar (MGC, Japan) were used for H9c2 cells hypoxia. The AnaeroPack could consume all the oxygen and release equivalent carbon dioxide within thirty minutes and the mixed gases in the anaerobic jar were CO₂ and N₂. Culture medium was changed into DMEM (Gibco, USA) without glucose and serum before hypoxia. Ad-HGF (12.5, 25 or 50 MOI) or HGF (5, 20 or 80 ng/ml) or HGF receptor inhibitor SU11274 (10 μM) was added into medium before hypoxia in different groups. H9c2 cells, anaerobic indicator and AnaeroPack were placed into the anaerobic jar and the jar lid was immediately closed. After about thirty minutes, the oxygen concentration decreased to less than 0.1%. The whole anoxic process was performed at 37°C.

Transmission electron microscope examination

After treatment, the cells were collected using 0.25% trypsin (containing 0.02% EDTA) digestion, washed in fresh PBS (pH=7.4), and fixed with 2.5% glutaraldehyde. The cells were then washed with 0.1 M cacodylate buffer, post-fixed with 1% osmium tetroxide and 1.5% potassium ferrocyanide for 1 h, stained with 1% aqueous uranyl acetate for 30 min, dehydrated through a graded series of ethanol to 100%. Cells were then infiltrated and embedded in TAAB Epon (Marivac Canada Inc., St. Laurent, Canada). Ultrathin section (60 nm) was cut on a Reichert Ultracut-S microtome, placed onto copper grids, stained with uranyl acetate and lead citrate, and observed on a transmission electron microscope (JEM-1010; JEOL, Tokyo, Japan) at an accelerating voltage of 80 kV.

Western blot

Protein was isolated using RIPA lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and protease inhibitor cocktail, Beyotime, Shanghai, China) supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF, Sigma-Aldrich, St. Louis, MO, USA), and was quantified using BCA Protein Assay (Pierce, Rockford, IL, USA). Electrophoresis was performed on SDS-PAGE gels. Separated proteins were transferred from the gels to PVDF membranes (Millipore, Billerica, MA, USA) and immunoblotting was performed as previously described [23].

TUNEL assay

TUNEL Cell Death Detection kit (Cat. No. 11684795910, Sigma, USA) for in situ apoptosis detection, was used for labeling DNA strand breaks, by terminal deoxynucleotidyl transfer-
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis

ase (TdT), which catalyzes polymerization of labeled nucleotides to free 3'-OH DNA ends in a template-independent manner (TUNEL-reaction). The heart sections or the cells were treated according to the manufacturer’s instructions and co-stained with cardiac tropo

ninin I and DAPI. A fluorescence microscope (Nikon, Tokyo, Japan) was used to observe the TUNEL-positive cells, and Image J (NIH) software was used to analyze the images. Data presented in the following text are the averages calculated from five different fields.

**Immunofluorescence**

Rat Hearts were embedded in OCT (Sakura, Japan) and cut into 8 μm sections which were stored at -80°C. H9c2 cells were cultured on coverslips, and fixed in 4% paraformaldehyde after the indicated treatment. Immunofluorescence was conducted as briefly described below. Sections were fixed in cold acetone at -20°C and placed in the fume hood to ventilate for 20 minutes. The slides were gently rinsed twice with PBS and permeabilized with 0.1% Triton X-100 for 10 minutes. The slides were rinsed twice with PBS and then blocked in 2.5% BSA in PBS for 30 minutes. Sections were incubated with ProteoStat® aggresome detection reagent, p62 (1/300 dilution), RIP1 (1/200 dilution) or RIP3 (1/300 dilution) diluted in the blocking buffer at 4°C overnight. Prior to the addition of the secondary antibody, the slides were rinsed three times with PBS. Secondary antibodies were added in the same blocking buffer (for green light: use 1/200 dilution of fluorescein and for red light: use 1/400 dilution of CY3 or Rhodamine labeled secondary antibodies) for 1 hour in the dark, followed by another three washes in PBS. The sections were mounted with VECTASHIELD mounting medium with Diamidino-2-phenylindole (DAPI), (Vector Laboratories, Burlingame, CA, USA), and captured images under LSM 5 Live DuoScan Laser Scanning Microscope (Zeiss, Oberkochen, Germany).

**Detection of aggresomes**

The ProteoStat® Aggresome Detection Kit (Enzo Life Sciences, Switzerland) were used for the detection of aggresomes in cells. The ProteoStat® aggresome detection reagent is a kind of 488 nm excitable red fluorescent molecular rotor which binds selectively to protein cargo within aggresomes. All components of the ProteoStat® Aggresome Detection Kit were prepared and the procedures were conducted according to the manufacturer’s instructions.

**CCK-8 assay**

Cell viability was assessed by the cell counting kit-8 (CCK-8) (KeyGEN BioTECH, China). Cells were seeded into 96-well plates at 4×10⁴ per well. After indicated treatment, a total of 10 μl CCK-8 was added to each well and incubated at 37°C in the dark for 2 hours and then the absorbance at 450 nm was measured with a microplate reader (BioTek, USA).

**Hoechst 33342 staining**

Typical morphological features of apoptotic cells were evaluated by Hoechst 33342 staining (KeyGEN BioTECH, China). After indicated treatment, the cells were washed twice with cold phosphate buffer saline (PBS) and fixed in 4% paraformaldehyde for 20 minutes. Cells were then washed with cold PBS again before incubated with 5 μg/ml Hoechst 33342 for 15 min at 37°C in the dark. Finally, cells were washed with PBS and apoptotic cells were identified under the fluorescence microscope (Nikon, Tokyo, Japan). Normal cells showed homogeneous blue chromatin with organized structure. By contrast, apoptotic cells showed bright blue chromatin which is highly condensed or fragmented.

**Flow cytometry analysis**

The necroptotic cells were identified by propidium iodide (PI) staining and flow cytometry analysis as previously described [7, 24]. Briefly, the adherent cells were detached by 0.25% trypsin digestion and washed in fresh PBS (pH=7.4). After centrifugation at 1000 rpm, cells were resuspended in cold PBS with 2 μg/ml PI for 3 minutes before measurement of red fluorescence for 10000 cells using Flow cytometry.

**RNA interference**

Two different siRNAs targeted RIP1, RIP3 and MLKL, respectively, and a negative control siRNA were designed by GenePharma Co., Ltd. (Shanghai, China). Below were the siRNA sequences: RIP1-sh#1: 5'-CCA CUA GUC UGA CGG AUA A-3', RIP1-sh#2: 5'-GCA CAA ATA CGA ACT TCA A-3', RIP3-sh#1: 5'-UAA CUU GAC GCA ACT TCA A-3', RIP3-sh#2: 5'-GCA CAA ATA CGA ACT TCA A-3', MLKL-sh#1: 5'-CAA ACU UCC UGG UAA CUC A-3'.
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis and MLKL-sh#2: 5'-GCG TAT ATT TGG GAT TTG CAT-3'. X-tremeGENE siRNA Transfection Reagent (invitrogen) was used to perform the siRNA knockdowns according to the manufacturer’s protocol. Briefly, 1.2×10^6 cells were seeded in 35-mm dishes to obtain approximately 80% confluence. A mixture containing 200 μl of siRNA (2.5 μg for each) and transfection reagent (14 μL for each) was added into the cells for 7 h at 37°C. Then change the old culture medium with fresh medium. The RIP1, RIP3 and MLKL expression levels were examined using western blot analysis.

Immunoprecipitation

Cells were lysed by IGEPAL CA-630 buffer (50 mM Tris-HCl (pH 7.4), 1% IGEPAL CA-630, 10 mM EDTA, 150 mM NaCl, 50 mM NaF, 1 μM leupeptin and 0.1 μM aprotinin). Primary antibody was covalently immobilized on protein A/G agarose using the Pierce® Crosslink Immunoprecipitation Kit according to the manufacturer’s instructions (Thermo Fisher Scientific, USA). Samples were incubated with immobilized antibody beads for at least two hours at 4°C. After IP, the samples were washed with TBS five times, then eluted with glycine-HCl (0.1 M, pH=3.5) and the immunoprecipitates were subjected to immunoblotting using specific primary antibodies and conformation-specific secondary antibody that recognizes only the native IgG (Cell Signaling, USA).

Statistical analysis

Data from at least three independent experiments were used to calculate the mean ± standard deviation (SD) using SPSS 18.0 statistical software. Statistical analyses between groups were performed by unpaired Student’s t test or one-way ANOVA followed by a post hoc Fisher's comparison test. A value of less than 0.05 was considered significant.

Results

Autophagy, apoptosis and necroptosis occurred in the heart after myocardial infarction

Firstly, we investigated how the three types of cell death distributed in the heart after myocardial infarction. LC3-II was a widely used indicator to mark autophagy [13]. We found LC3-II staining significantly increased in the heart 7 days and 28 days after MI. Moreover, in 7 days' heart of MI, LC3-II staining was mainly concentrated in the infarcted area, which indicating more autophagy happened in the infarct zones than the peri-infarct zones. Inversely, in 28 days' heart autophagy in peri-infarct zones was significantly higher than the infarct zones, but both of which were lower than the 7 days' heart with MI. And there was no difference of autophagy in the non-infarct zone among the three groups (Figure 1A). Next, we used TUNEL staining to examine the apoptosis level in the heart following MI. More cardiomyocytes apoptosis occurred after MI. In 7 days’ and 28 days’ cardiac tissues of MI, apoptosis mainly appeared in the peri-infarct zones rather than the infarct zones. When compared with the 7 days’ heart of MI, 28 days’ heart showed lower apoptosis level. No difference of apoptosis level was observed in the non-infarcted areas of the indicated three groups (Figure 1B). Necroptosis was evaluated using PI labeling by intra-peritoneal injection of PI one hour before termination [25]. Cardiomyocyte necroptosis significantly increased after MI. Intriguingly, we found much more necroptosis appeared in the infarct zones than the other areas in both 7 days’ and 28 days’ hearts of MI. Furthermore, necroptosis in the infarct zones of the 28 days’ heart markedly declined as compared with the 7 days’ heart. Necroptosis level showed no difference in the non-infarcted areas of the indicated three groups (Figure 1C). These data confirmed that autophagy, apoptosis and necroptosis occurred in the heart after myocardial infarction.

Ad-HGF treatment improved the cardiac remodeling by upregulating autophagy and necroptosis and inhibiting apoptosis after MI

Ad-HGF and Ad-null vectors were injected into three sites of the myocardium in proximity to the ischemic area immediately after ligation of the LAD. One week after the injection, the expressions of HGF, Met and p-Met were analyzed by western blot. The results showed Ad-HGF treatment significantly increased the HGF and p-Met expression level in the cardiac peri-infarct zones than the Ad-null and sham groups (Figure 2A). The representative M-mode echocardiograms of SD rats showed that motion range of the left ventricular anterior wall weakened at 1 week after MI. After 4 weeks, the abnormality of anterior wall movement was...
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis

Figure 1. Autophagy, apoptosis and necroptosis occurred in the heart after myocardial infarction. A. Representative immunofluorescent images of staining with LC3-II (green), cTnI (red), and DAPI (blue) in the heart tissue of SD rats 7 days, 28 days after coronary artery ligation are shown. The white arrow indicates the infarct zones and yellow arrow indicates the peri-infarct zones. The scale bar in the lower left corner of image is 60 μm. Below is the same.

The motion range of the left ventricular anterior wall was much better in MI+Ad-HGF treatment group than MI+Ad-null group. LVEF and LVFS were evaluated by measurements of echocardiography. Compared with the sham group, LVEF and LVFS both significantly decreased in MI group 1 week after ligation. However, Ad-HGF treatment group showed significantly improvement in LVEF and LVFS than the MI+Ad-null group 4 weeks after MI (Figure 2B). Cardiac fibro-
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis.
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis.
sis is a well-known feature of cardiac remodeling after MI [26]. Masson-Trichrome staining revealed that the MI scar size and cardiac fibrosis were significantly attenuated in Rat receiving Ad-HGF treatment as compared to Ad-null group 28 days after MI (Figure 2C). Heart failure is often accompanied by accumulation of damaged proteins and organelles, in the form of aggresomes [8]. Microscopic analyses of the chronic MI rat heart showed that aggresomes accumulated in the perinucleus of border zone and remote area cardiomyocytes (Figure 2D). The aggresomes co-localized with p62/SQSTM1 (p62), a protein known to be degraded by autophagy, suggesting insufficient clearance of aggresomes by autophagy (Figure 2D). The accumulation of aggresomes and p62 was markedly attenuated in rat with Ad-HGF treatment as compared to the Ad-null group, suggesting that endogenous HGF positively affects protein and organelle quality control in post MI hearts. Autophagy is activated in the post MI heart, as evidenced by increases in LC3-II protein level. Beclin-1 and LC3-II protein level were further upregulated and p62 was downregulated in Ad-HGF-treated rat after MI, which proved the promoting autophagy effects of Ad-HGF treatment (Figure 2E). Cleaved caspase 3/caspase 3 protein level, indicator of apoptosis, significantly increased after MI and was markedly attenuated after Ad-HGF treatment which was related to the increase of the anti-apoptotic proteins, Bcl-2 and Bcl-xL, and the decrease of the pro-apoptotic protein, Bax level (Figure 2F). The protein levels of RIP1/3 are positively correlated with the extent of necroptosis [17]. Therefore, we examined the expression levels of RIP1 and RIP3 in the MI heart. Western blot analysis showed that the levels of these two proteins were significantly increased in cardiac tissues following MI. And Ad-HGF treatment further increased the level of RIP1 and RIP3 (Figure 2G). Taken together, these results suggest that Ad-HGF treatment improved the cardiac remodeling by upregulating autophagy and necroptosis and inhibiting apoptosis after MI.

In vitro hypoxia treatment induced autophagy, apoptosis and necroptosis in H9c2 cells

The insufficient supply of oxygen and nutrients results in the damages to the heart after MI. To mimic the pathological process of MI, we treated rat myocardial cell line, H9c2 cell, with serum-free and glucose-free medium in a hypoxia chamber. To discern which type of cell death occurred in H9c2 cells after the insult, we used TEM to observe cellular morphology. After ischemia and hypoxia treatment, all types of cell death, including apoptosis, necroptosis, and necrosis, were observed in H9c2 cells (Figure 3A). Compared with the normal structure of H9c2 cell under normoxia (Figure 3Aa), TEM detected the formation of representative autophagosome in H9c2 cells at 3 h of hypoxia (Figure 3Ab). Apoptotic cell characterized by chromatin condensation and nuclear fragmentation is seen at 6 h of hypoxia (Figure 3Ac). The morphological changes of necroptosis cells are distinct from that of autophagy and apoptosis. In contrast to autophagic (Figure 3Ab) and apoptotic cells (Figure 3Ac), membrane leakiness, organelle and nuclear swelling, increased cell volume with translucent cytoplasm were observed to occur in necroptosis cells at 9 h of hypoxia (Figure 3Ad); but autophagosomes and apoptotic bodies were not formed in these cells. We further investigated the changes of...
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis

Figure 3. In vitro hypoxia treatment induced autophagy, apoptosis and necroptosis in H9c2 cells. (A) Transmission electron microscope (TEM) was used to observe cellular morphology changes. a. Control group showing the viable H9c2 cell morphology, (b-d) Hypoxia groups, (b) TEM detected autophagosomes in H9c2 cells after hypoxia for 3 h. (c) Apoptotic cell showing nuclear shrinkage and chromatin condensation was observed in H9c2 cells after hypoxia for 6 hours. (d) Necroptotic cell showing swollen nucleus, increased cell volume and disrupted cell membrane integrity with translucent cytoplasm was observed in H9c2 cell after hypoxia for 9 hours. (B) Western blot showing the LC3-I, LC3-II, cleaved caspase 3, caspase 3, RIP1, RIP3 protein levels in H9c2 cells after hypoxia for indicated hours. β-actin was used as the loading control. (C-F) Showing the quantitative analysis of the above protein levels after hypoxia for indicated hours, respectively. Data are expressed as mean ± SD, n=4.

the relative proteins indicating autophagy, apoptosis and necroptosis under hypoxia, respectively. Previous studies have demonstrated that LC3 are autophagy-related proteins and enhanced autophagy accompanied by increased LC3-II expression [10]. The results of the western blot showed autophagy significantly increased soon after hypoxia and reached the summit at 3 h under hypoxia, then
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis.

However, we intriguingly observed autophagy level increased again at 15 h and reached the second summit at 18 h after hypoxia, and then declined (Figure 2B and 2C).

The changes of cleaved caspase 3/caspase 3 protein level revealed that apoptosis process started after hypoxia and got to the peak at 6 h, and then slowly went down (Figure 2B and 2D). The protein levels of RIP1/3 are positively correlated with the extent of necroptosis [17].

Figure 4. HGF promotes autophagy in H9c2 cells under hypoxia. A. Confocal microscopy analysis of H9c2 cells transiently overexpressing mRFP-GFP-LC3. HGF (80 ng/mL), SU11274 (10 μM) or PBS was added into medium and hypoxia for 3 hours and normoxic group was shown as the control. The bar graph showed the statistical analysis of fluorescent points in H9c2 cells. B, C. Western blot analysis for LC3-I, LC3-II, Beclin-1 and p62/SQSTM1 protein levels in H9c2 cells after Ad-HGF (0, 12.5, 25, 50 MOI) overexpression or SU11274 (10 μM) treatment and hypoxia for 3 hours. The bar graph showed the quantitative analysis of the above protein levels. D. Fluorescent microscopy analysis of H9c2 cells staining with ProteoStat® aggregates detection reagent (red), p62/SQSTM1 (green) and DAPI (blue) in Control, Hypoxia, Hypoxia+Ad-HGF and Hypoxia+Ad-HGF+SU11274 groups. The bar chart showed the statistical analysis of cells with perinuclear p62/aggresomes relative level in the indicated groups. All results are expressed as mean ± SD, n=3, *P<0.05.
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis

expressions of the two proteins markedly increased under hypoxia insult and lasted 3 hours before gradually falling down. Collectively, the results demonstrated that hypoxia treatment induced autophagy, apoptosis and necroptosis in H9c2 cell in vitro.

**HGF promotes autophagy in H9c2 cells under hypoxia**

To explore the effect of HGF on autophagy in H9c2 cells under hypoxia, we used Ad-mRFP-GFP-LC3 adenovirus infection. Only when autophagy occurs, mRFP and GFP tagged LC3 gathered together and formed fluorescence points which could be counted under fluorescence microscope. In merged images, red points represented autolysosome while yellow (merged by green and red points) represented autophagosome. As expected, both autophagosome and autolysosome were significantly increased in H9c2 cells after hypoxia. Moreover, the addition of HGF markedly promoted the formation of autophagosome and autolysosome in H9c2 cells under hypoxia. SU11274, inhibitor of HGF receptor, reversed the function of HGF on autophagy (Figure 4A). Because Ad-HGF was used in our study in vivo, we further investigated the impact of Ad-HGF infection with different multiplicity of infection (MOI) on the autophagy level in H9c2 cell under hypoxia. The appropriate MOI of Ad-HGF to infect the H9c2 cells had been explored and we chose the 12.5, 25, 50 MOI of Ad-HGF for the following experiments (Supplementary Figure 1). Ad-HGF (12.5, 25, 50 MOI) gradually increased the HGF and p-Met protein levels in H9c2 cells under hypoxia which could be blocked by SU11274. Our results demonstrated Ad-HGF worked well at the selected MOIs (Supplementary Figure 1). As expected, Ad-HGF (12.5, 25, 50 MOI) dose-dependently increased the LC3-II protein level in H9c2 cells under hypoxia, which was weakened by the SU11274 (10 μM) (Figure 4B). Beclin1 plays an important role in both autophagosome formation and autolysosome fusion [27]. Ad-HGF significantly increased Beclin-1 protein level in H9c2 cells under hypoxia in a dose-dependent fashion. Meanwhile, Ad-HGF markedly decreased p62 level by upregulating autophagy level. These impacts of Ad-HGF on autophagy could be reversed by SU11274 (Figure 4C). Heart failure is often accompanied by accumulation of damaged proteins and organelles, in the form of aggresomes [8]. Our study in vivo has confirmed Ad-HGF treatment could decrease the aggresomes accumulated in the cardiomyocytes after MI. Here, we showed the accumulation of aggresomes and p62 was markedly attenuated with Ad-HGF treatment (Figure 4D), which confirmed HGF promoted autophagy and reduced the accumulation of damaged proteins or organelles in H9c2 cells under hypoxia.

**HGF inhibits apoptosis in H9c2 cells under hypoxia**

Next, we assessed the impact of HGF on apoptosis in H9c2 cells under hypoxia. Hoechst staining of apoptosis showed hypoxia resulted in the significant increase of H9c2 cells apoptosis. Pre-infection of Ad-HGF markedly reduced the apoptosis percent of H9c2 cells under hypoxia, which could be blocked by SU11274 inhibitor (Figure 5A). The anti-apoptotic effect of HGF was further confirmed by the TUNEL assay (Supplementary Figure 2). Further western blot analysis revealed that Ad-HGF treatment significantly decreased the cleaved caspase 3/caspase 3 protein level in H9c2 cell under hypoxia in a dose-dependent manner (Figure 5B). To further explore the anti-apoptotic mechanism of HGF, we tested the pro-apoptotic Bax protein and the anti-apoptotic Bcl-2 and Bcl-xL protein levels. Ad-HGF overexpression significantly inhibited the rise of Bax protein and increased Bcl-2 and Bcl-xL protein levels in H9c2 cells. SU11274 could reverse the protective function of Ad-HGF on H9c2 cells under hypoxia insult (Figure 5C). These data confirmed HGF indeed inhibited apoptosis in H9c2 cells under hypoxia.

**HGF promotes necroptosis in H9c2 cells under hypoxia**

Necroptosis occurring in cardiac tissues of MI and H9c2 cells under hypoxia has been demonstrated in our foregoing study. Here, we mainly investigated the impact and mechanism of HGF on necroptosis in H9c2 cells under hypoxia. Propidium iodide (PI) staining has been widely used to mark necroptotic cells [7, 24]. The flow cytometric analysis of PI staining showed HGF treatment significantly increased the percent of necroptotic cells under hypoxia, which was alleviated by c-Met receptor inhibitor, SU11274 (Figure 6A). Both the western blot and immuno-
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis

Figure 5. HGF inhibits apoptosis in H9c2 cells under hypoxia. A. Fluorescent microscopy analysis showed the Hoechst staining of apoptosis in H9c2 cells from the control, hypoxia, hypoxia+Ad-HGF and hypoxia+Ad-HGF+SU11274 groups, respectively. The bar chart described the statistical analysis of the percent of apoptotic cells. B, C. Western blot detection of cleaved caspase 3, caspase 3, Bax, Bcl-2 and Bcl-xL levels in H9c2 cells after the indicated treatment. β-actin is shown as a loading control. The bar graphs displayed the quantitative analysis of the protein levels. Data are expressed as mean ± SD, n=3, *P<0.05.

fluorescence analyses revealed the Ad-HGF treatment markedly enhanced the expressions of RIP1 and RIP3 proteins indicating the extent of necroptosis in H9c2 cell under hypoxia (Figure 6B and 6C). In addition, the immunofluorescence results showed RIP1 and RIP3 proteins displaying diffuse distribution but colocalization in the cells (Figure 6C). Previous studies have demonstrated RIP1/RIP3 complex, namely necrosome, plays a dominant role in mediating the downstream necroptosis process [17, 28]. To verify the impact of HGF on the specific interaction between RIP1 and RIP3 in H9c2 cells under hypoxia, we used co-immunoprecipitation assay to detect the changes of RIP1/RIP3 complex in H9c2 cells. The RIP1/RIP3 complex was present in living H9c2 cells, but the amount of RIP1/RIP3 complex markedly increased by Ad-HGF intervention upon hypoxia induction, which was rescued by SU11274 (Figure 6D). MLKL has been reported to be the executioner of necroptosis signaling [14]. Our further study confirmed Ad-HGF overexpression dose-dependently enhanced MLKL protein level in H9c2 cells under hypoxia induction (Figure 6E). Knockdown of RIP3 or RIP1 in...
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis.

A

B

C

D

E

4618  
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis

H9c2 cells decreased the MLKL protein level under hypoxia, but knockdown of MLKL has no impact on the protein level of RIP1 and RIP3 (Figure 6F-H). These findings implicated MLKL as a key mediator of necrosis signaling downstream of the RIP1/RIP3 complex, which is consistent with previous report [17]. Collectively, these results proved that HGF promotes necroptosis in H9c2 cells under hypoxia.

HGF regulated the interplay among autophagy, apoptosis and necroptosis

The above data confirmed HGF upregulated autophagy and necroptosis and inhibited apoptosis in H9c2 cells under hypoxia. Here, we further addressed how HGF regulated the interplay among autophagy, apoptosis and necroptosis. We first evaluated whether HGF affects interaction between Bcl-2 and Beclin1, or Bax using co-immunoprecipitation assays in H9c2 cells. Interestingly, Ad-HGF treatment significantly decreased binding of Bcl-2 to Beclin1 but enhanced Bcl-2 binding to Bax in H9c2 cells under hypoxia (Figure 7A and 7B).

These data suggested HGF treatment induced the dissociation of Beclin-1 from the Beclin-1/Bcl-2 complex, which may offer the chance for beclin-1 protein to be active in promoting autophagy. Furthermore, HGF-induced sequestration of Bax by Bcl-2 allows Bax to become
inactive, thereby inhibiting apoptosis. The Beclin1-Vps34-Atg14L complex plays an important role in promoting the autophagosome formation [29]. We further used co-immunopre-
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis
cipitation assay to examine whether Beclin1 dissociating from Beclin-1/Bcl-2 complex induced by HGF joined the formation of Beclin1-Vps34-Atg14L complex. As expected, Ad-HGF treatment significantly increased the formation of Beclin1-Vps34-Atg14L complex in H9c2 cells under hypoxia (Figure 7C), which accounted for promoting autophagy.

Active caspase-8 induces apoptosis and inhibits necroptosis by cleaving RIP1/RIP3 complex. When caspase-8 is inhibited, the amyloid RIP1/RIP3 necrosome is formed and necroptosis ensued [17, 30]. We next analyzed whether HGF regulated caspase 8, thereby affecting apoptosis and necroptosis. Hypoxia markedly increased the cleaved caspase 8 protein level in H9c2 cells which was significantly decreased by Ad-HGF treatment in a dose-dependent fashion (Figure 7D). The protease activity test also demonstrated Ad-HGF reduced the caspase 8 activity in H9c2 cells under hypoxia (Figure 7E). Thus, Ad-HGF treatment weakened caspase 8 activity in H9c2 cells under hypoxia, on the one hand, inhibiting apoptosis and on the other hand, promoting necroptosis.

To elucidate the overall effect of Ad-HGF on H9c2 cells under hypoxia, we used CCK-8 assay to assess the cell activity after Ad-HGF treatment. Interestingly, Ad-HGF significantly improved cell vitality under the hypoxia injury (Supplementary Figure 3A), which may be due to the pro-survival properties of HGF on the whole.

Our study in vivo and in vitro has confirmed Ad-HGF promoted autophagy and necroptosis and inhibited apoptosis in cardiac tissues and H9c2 cells under hypoxia. But the effect of these results on the normal cells is still unknown. We therefore investigated the effect of the supernatant from H9c2 cells under hypoxia after Ad-HGF treatment on the vitality of H9c2 cells in normoxic culture. Surprisingly, we found the supernatant from H9c2 cells of Ad-HGF treatment under hypoxia dramatically increased the vitality of H9c2 cells in normoxic culture for 24, 48 and 72 hours. In addition, the supernatant from H9c2 cells under hypoxia alone also enhanced the vitality of H9c2 cells in normoxic culture for 24 hours than the control, but showed no significant difference between them in later 48 or 72 hours’ incubation (Supplementary Figure 3B-D). In summary, we confirmed supernatant from H9c2 cells of Ad-HGF treatment under hypoxia improved the cell vitality in normoxic culture, which may indirectly reflect the effect of Ad-HGF on the normal myocardial tissue around the infarct zones. And the beneficial substances existed in the supernatant from cells of Ad-HGF treatment under hypoxia warrants further investigation.

Discussion
We firstly showed that the distribution of autophagy, apoptosis and necroptosis differs in temporal and spatial context after MI. The main findings of our study were that: (1) Ad-HGF treatment improves the cardiac remodeling of SD rats following MI by upregulating autophagy and necroptosis and inhibiting apoptosis, (2) which is associated with the regulation of the interplay among autophagy, apoptosis and necroptosis.

Adverse remodeling after MI is a big challenge worldwide. Although substantial progress has been achieved in lowering acute mortality rates after AMI, much of the ongoing morbidity and mortality relates to chronic adverse remodeling that occur after infarction [2]. And the numbers of cell death in MI is the most critical determinant of subsequent left ventricular remodeling and heart failure [31]. For many years, apoptosis was considered as the only form of regulated cell death and studies investigating MI mainly focused on apoptosis [3, 4]. Recent years, autophagy and necroptosis have been found to be another two regulated cell death styles existing in various diseases including MI [5-7]. Recent few studies have focused on autophagy or necroptosis in MI [7, 32]; however, whether the whole of three cell death styles in MI affect subsequent cardiac remodeling process is still largely unknown.

In order to tackle these issues, we firstly investigated the distribution of autophagy, apoptosis and necroptosis in cardiac tissues after MI. Interestingly, we find autophagy, apoptosis and necroptosis differs in temporal and spatial context after MI, although all of them significantly increased after MI. In 7 days’ heart of MI, LC3-II staining was mainly concentrated in the infarcted area, which indicating more autophagy occurred in the infarct zones than the peri-infarct zones. Inversely, in 28 days’ heart autophagy in peri-infarct zones was markedly
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis

higher than the infarct zones, but both of which were lower than the 7 days' heart with MI. However, apoptosis mainly appeared in the peri-infarct zones rather than the infarct zones in 7 days' and 28 days' heart after MI. When compared with the 7 days' heart of MI, 28 days' heart showed lower apoptosis level. No difference of apoptosis level was observed in the non-infarcted areas of the three investigated groups. Necroptosis was evaluated using PI labeling by intraperitoneal injection of PI one hour before termination [25]. Intriguingly, we found much more necroptosis appeared in the infarct zones than the other areas in both 7 days' and 28 days' hearts of MI. Furthermore, necroptosis in the infarct zones of the 28 days' heart markedly declined as compared with the 7 days' heart, but showed no difference in the non-infarcted areas of the three groups. These results offer us new evidence about the distribution of autophagy, apoptosis and necroptosis after MI, regulation of which affecting the cardiac remodeling need our further research.

As a secreted cytokine, HGF plays a protective role in MI [19]. But how HGF regulate autophagy, apoptosis and necroptosis and affect cardiac remodeling after MI has not been reported. HGF level enhances at the onset of MI, but declining after twenty four hours and returns to normal three days later [33]. In order to increase HGF expression level in the infarcted myocardium, meanwhile extending its expression time, we performed our study using adenovirus vector carrying HGF (Ad-HGF), which with CMV promoter could achieve summit expression in myocardial tissue on the first day post-injection and can be maintained for at least four weeks [21].

Our results confirmed Ad-HGF treatment significantly improving the cardiac remodeling by increasing the HGF and p-Met expression level in the cardiac peri-infarct zones of SD rat. Several observations were particularly noteworthy. Firstly, we found that Ad-HGF improved cardiac function including preserving LVEF and LVFS 28 days after MI. Secondly, cardiac fibrosis was attenuated with Ad-HGF treatment. Thirdly, the accumulation of aggresomes indicating damaged organelles and protein aggregates in chronic heart failure was markedly reduced after Ad-HGF intervention. Taken together, these data demonstrate that Ad-HGF improves cardiac remodeling after MI in rat, culminating in better preserved cardiac structure and function. To determine how Ad-HGF regulates autophagy, apoptosis and necroptosis after MI, the changes of accordingly representative proteins including autophagy markers, Beclin-1, LC3-II, P62, apoptotic markers, cleaved caspase 3, caspase 3, necroptotic markers, RIP1 and RIP3 were interrogated. The results confirmed Ad-HGF promoted autophagy and necroptosis and inhibited apoptosis after MI.

To validate the phenomenon observed in vivo and investigate the underlying mechanisms, we further perform the study in vitro. Model of ischemic hypoxemia was used to mimic in vivo myocardial infarction [34] and rat myocardial cell line, H9c2 cell was employed for later research. Using TEM method, we observed the typical cell morphological characteristics of autophagy, apoptosis and necroptosis in H9c2 cells under hypoxia, respectively. It’s worth noting that as early as 3 hours after hypoxia, autophagosomes were mainly observed, but apoptotic cell showing nuclear shrinkage and chromatin condensation was observed after hypoxia for 6 hours. Necrotic cell showing swollen nucleus, increased cell volume and disrupted cell membrane integrity with translucent cytoplasm was observed in H9c2 cell after hypoxia for 9 hours. These results indicate the threshold value of hypoxia injury for the occurrence of autophagy, apoptosis or necroptosis differs. Autophagy is the most sensitive to hypoxia, but necroptosis the least. This may be partly responsible for their different distributions of autophagy, apoptosis and necroptosis in the heart after MI. The related proteins of autophagy, apoptosis or necroptosis have changed after hypoxia for 3 hours, the rational explanation of which is that signaling pathways go first, then the results.

Autophagy is generally defined as a cellular program that ensures survival under conditions of stress. The ability of autophagy to clear damaged or denatured subcellular constituents such as aggregated protein as well as to maintain mitochondrial homeostasis appears to play important roles in the cytoprotective and homeostatic functions of autophagy [35]. In study in vitro, we confirmed Ad-HGF dose-dependently promoted autophagy in H9c2 cells under hypoxia. Ad-HGF treatment not only increased the number of autolysosome and
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis

autophagosome, raised the pro-autophagic proteins including LC3-II, Beclin-1, but also decreased the accumulation of damaged proteins and organelles, in the form of aggresomes. SU11274, a specific inhibitor of HGF's c-Met receptor, effectively block the impact of Ad-HGF on autophagy. These results are consistent with our findings in vivo. Upregulation of autophagy during myocardial stress is generally compensatory, alleviating energy loss and scavenging damaged mitochondria and protein aggregates [8], which is beneficial for the cardiac remodeling process after MI. One study reported agonist antibodies could activate the c-Met receptor and protect cardiomyocytes from cobalt chloride-induced autophagy [36]. In this study, cobalt chloride was employed to imitate cell chronic hypoxia, but we used serum-glucose free medium and anaerobic jar to mimic hypoxia for H9c2 cells. This may explain the conflict of the results.

Apoptosis, a parameter linked to fibrosis, occurs in nearly all models of cardiac remodeling [37]. Experimental models have substantiated the sufficiency of clinically relevant degrees of apoptosis to induce heart failure, as well as the necessity of myocyte apoptosis for the development of heart failure [38]. The anti-apoptotic effect of Ad-HGF on H9c2 cells under hypoxia was further demonstrated in our in vitro study, which was in accordance with our study in vivo and previous reports [39, 40]. Ad-HGF treatment markedly decreased the percent of apoptotic cells under hypoxia insult. Further research revealed that Ad-HGF enhanced the anti-apoptotic protein levels including Bcl-2 and Bcl-xL, meanwhile reducing the pro-apoptotic Bax level. These results highlight the therapeutic effects of Ad-HGF on cardiac remodeling after MI.

Necroptosis, a regulated form of necrosis, plays a vital role in development, tissue homeostasis, and disease pathogenesis [41]. To date, few studies have reported the relationship between HGF and necroptosis in MI. Our study, for the first time, confirmed HGF intervention increased the percentage of necrotic H9c2 cells under hypoxia. Previous studies have proved necroptosis is triggered by the interaction of RIP1 with RIP3, a serine/threonine kinase, resulting in the formation of necrosome [15, 16]. Our further results of both western blot and immunofluorescence confirmed Ad-HGF increased the RIP1 and RIP3 protein levels in H9c2 cell under hypoxia injury. In addition, the immunofluorescence also revealed RIP1 and RIP3 proteins displaying diffuse distribution but colocalization in the cells, which was validated by the co-immunoprecipitation that Ad-HGF indeed promoted the interaction between RIP1 and RIP3 proteins by enhancing RIP1-RIP3 necroptosome level. As the executor of necroptosis, MLKL activation results in its recruitment and oligomerization at phosphatidylinositol phosphates in the plasma membrane leading to plasma membrane rupture and cell death [42]. As expect, MLKL protein levels markedly increased in H9c2 cell after Ad-HGF treatment under hypoxia. Moreover, either knockdown of RIP1 or RIP3 by specific siRNA interference assay in H9c2 cells decreased the MLKL protein levels; however, knockdown of MLKL had no impact on RIP1 and RIP3 protein levels. These findings indicated MLKL as a key mediator of necroptosis signaling downstream of the kinase RIP1 and RIP3, which is in accordance with previous report [17]. Collectively, we confirmed Ad-HGF promoted necroptosis in H9c2 cells under hypoxia, which is in accordance with what we observed in vivo.

Being different from apoptosis and autophagy, the occurrence of necroptosis involves release of the dying cell's intracellular components, and the effects of this release on neighboring cells can yield inflammation [38, 42]. Inflammation is a multicellular process that destroys pathogens and promotes recovery from injury through a variety of cooperating changes, including cell death [43]. However, Mark Luedde and colleagues reported that RIP3-dependent necroptosis modulates post-ischaemic adverse remodeling in a mouse model of MI. In their study, mice deficient for RIP3 showed a significantly better ejection fraction and less hypertrophy in magnetic resonance imaging studies thirty days after MI with LAD ligation method [7]. The rational explanation is that the protective effect of HGF on cardiac remodeling after MI may come from the whole impact of HGF on autophagy, apoptosis and necroptosis, not merely necroptosis. This explanation was further supported by our observation that supernatant from H9c2 cells of Ad-HGF treatment under hypoxia significant-
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis

We have demonstrated Ad-HGF intervention promote autophagy and necroptosis and inhibit apoptosis in H9c2 cell under hypoxia. But how Ad-HGF regulates the interplay among autophagy, apoptosis and necroptosis need our further research. Our co-immunoprecipitation assays showed Ad-HGF treatment significantly decreased the binding of Bcl-2 to Beclin1 but enhanced Bcl-2 binding to Bax in H9c2 cells under hypoxia. These data indicate HGF induced the dissociation of Beclin-1 from the Beclin-1/Bcl-2 complex, which may offer the chance for Beclin-1 protein to be active in promoting autophagy. Moreover, HGF-induced sequestration of Bax by Bcl-2 allows Bax to become inactive, thereby inhibiting apoptosis. Studies reported the Beclin1-Vps34-Atg14L complex plays an important role in promoting autophagy by increasing the autophagosome formation [8, 29]. We further used co-immunoprecipitation assay to examine whether Beclin1 dissociating from Beclin-1/Bcl-2 complex induced by HGF joined the formation of Beclin1-Vps34-Atg14L complex. As expected, Ad-HGF treatment significantly increased the formation of Beclin1-Vps34-Atg14L complex in H9c2 cells under hypoxia, which accounted for promoting autophagy. Caspase-8 not only activates downstream caspases to bring about apoptosis, but also cleaves RIP1 and RIP3 abrogating their ability to signal necroptosis [17]. Both the western blot and caspase 8 activity assays showed Ad-HGF significantly decreased the caspase 8 protein and activity levels in a dose-dependent fashion, which obligated the cell to undergo necroptosis under hypoxia and block apoptosis.

In conclusion, the current study shows the distribution of autophagy, apoptosis and necroptosis differs in temporal and spatial context after MI. Ad-HGF treatment improves the cardiac remodeling of SD rats following MI by upregulating autophagy and necroptosis and inhibiting apoptosis, which is associated with the regulation of the interplay among them. Thus, our findings offer new evidence and strategies for the treatment of MI and post-MI cardiac remodeling.

Acknowledgements

This work has been funded by the National Natural Science Foundation of China (No. 81441011& No. 81170102/H0203), the Chinese Medical Association of the Sunlight Foundation (SCRFCMDA201217), the Fourth Period Project “333” of Jiangsu Province (BRA20122207), China, Supporting program of Science and Technology of Jiangsu (Social Development, BK2010021), Jiangsu provincial science and Technology Department basic research program (Natural Science Foundation of China BK20141020) and the Graduate Innovation Foundation of Jiangsu Province (JX22013341). We are indebted to Dr. Di Yang, Dr. Xiangjian Chen, Dr. Fang Wang and Dr. Huwen Zhang (The First Affiliated Hospital of Nanjing Medical University) for help with skillful technical assistance.

Disclosure of conflict of interest

None.

Address correspondence to: Zhijian Yang, Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, Jiangsu, China. Tel: (+86) 025-68136076; Fax: (+86) 025-84352775; E-mail: zhijianyangnj@njmu.edu.cn

References

Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis


Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis


Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis


Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis.
**Supplementary Figure 1.** Choose the appropriate multiplicity of infection (MOI) of Ad-HGF to infect the H9c2 cells. A. Different MOIs of Ad-HGF (1000, 100, 10, 1, 0.1 MOI) were used to infect the H9c2 cells with the same cell density for 24 hours and the GFP fluorescence conjugated was observed under the fluorescence microscope. The infection efficiency of Ad-HGF (1000 or 100 MOI) was high, but the number of dead cells after infection increased. B-D. CCK-8 assay was further used to assess the cell activity after infection of Ad-HGF with various MOIs. a. control, b. MOI=1000, c. MOI=200, d. MOI=100, e. MOI=50, f. MOI=25, g. MOI=12.5, h. MOI=6.125. The infection for 24, 48 or 72 hours’ CCK-8 assay showed the cell activity with Ad-HGF (1000, 200, 100 MOI) was at least once significantly decreased when compared with the control. E-G. The HGF levels in supernatant after Ad-HGF (1000, 200, 100, 50, 25, 12.5, 6.125 MOI) infection for 24, 48 or 72 hours were determined by the ELISA assay. Combined the above assays, we chose the 50, 25, 12.5 MOI of Ad-HGF for the following experiments. Data are expressed as mean ± SD, n=3, *P<0.05 vs. the control, **P<0.01 vs. the control, ***P<0.001 vs. the control. H. Western blot analyzed the protein levels of HGF and p-Met in H9c2 cells under hypoxia after Ad-HGF (12.5, 25, 50 MOI) or SU11274 (10 μM) treatment. β-actin was used as loading control. I, J. The bar graphs showed the statistical analysis of the above protein levels. Data are shown as mean ± SD, n=3, *P<0.05.
Ad-HGF promotes autophagy and necroptosis and inhibits apoptosis

Supplementary Figure 2. HGF treatment decreased the apoptotic H9c2 cells under hypoxia. A. Fluorescence microscope analysis of the TUNEL and DAPI staining in H9c2 cells showed hypoxia increased the percent of apoptotic cells which was significantly attenuated by HGF (80 ng/ml). B. The bar chart displayed the statistical analysis of the percent of the apoptotic cells. Data are expressed as mean ± SD, n=3, *P<0.05.

Supplementary Figure 3. Treatment of Ad-HGF or its cell supernatant increased the activity of H9c2 cells. A. CCK-8 assay evaluated the activity of H9c2 cells under hypoxia after the indicated treatment. Ad-HGF dose-dependently increased the cell activity under hypoxia when compared to the control group, which was blocked by SU11274. Representative images were shown. B-D. The activities of H9c2 cells treated with the hypoxia supernatant for 24, 48 or 72 hours were determined by CCK-8 assay. Treatment groups: 1. Supernatant of H9c2 cells in normoxic group, 2. Supernatant of H9c2 cells under hypoxia for nine hours, 3. Supernatant of H9c2 cells under hypoxia for nine hours after infected with Ad-HGF (12.5 MOI), 4. Supernatant of H9c2 cells under hypoxia for nine hours after infected with Ad-HGF (25 MOI), 5. Supernatant of H9c2 cells under hypoxia for nine hours after infected with Ad-HGF (50 MOI), 6. Supernatant of H9c2 cells under hypoxia for nine hours after treated with Ad-HGF (50 MOI) and SU11274 (10 μM). The results revealed the supernatant of H9c2 cells under hypoxia after infected with Ad-HGF significantly enhanced the cell activity when compared with the control and the group of hypoxia supernatant without Ad-HGF infection. The hypoxia supernatant without Ad-HGF infection markedly increased the cell activity in 24 hours' incubation than the control, but showed no significant difference between them in later 48 or 72 hours' incubation. Data are expressed as mean ± SD, n=3, *P<0.05 vs. control, &P<0.05 vs. the control, #P<0.05 vs. the group 5.